Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to $360,000.

  • Arcutis Biotherapeutics' Other Non-Current Liabilities fell 14.29% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $360,000, marking a year-over-year decrease of 14.29%. This contributed to the annual value of $570,000 for FY2024, which is 32.86% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Other Non-Current Liabilities is $360,000, which was down 0.00% from $360,000 recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Other Non-Current Liabilities high stood at $849,000 for Q4 2023, and its period low was $12,000 during Q2 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $360,000 (2025), whereas its average is $427,375.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 83.97% in 2021, then soared by 85.57% in 2025.
  • Arcutis Biotherapeutics' Other Non-Current Liabilities (Quarterly) stood at $25,000 in 2021, then plummeted by 52.00% to $12,000 in 2022, then reached $849,000 in 2023, then slumped by 32.86% to $570,000 in 2024, then declined by 14.29% to $360,000 in 2025.
  • Its Other Non-Current Liabilities stands at $360,000 for Q3 2025, versus $360,000 for Q2 2025 and $360,000 for Q1 2025.